PHGD yields 666666.67% · ABBV yields 3.12%● Live data
📍 PHGD pulled ahead of the other in Year 1
Combined, PHGD + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PHGD + ABBV for your $10,000?
Phil-Good Products, Inc produces and sells injection molded plastic parts and components. The company provides machining services, including mold making, maintenance, and repairing; precision machining; prototyping; product development; EDM; milling; lathe; surface grinding; and solid work services. It also offers injection molding services, such as plastic parts molding, prototyping and mold testing, short and long run, insert molding, mold trial and material sampling, and turn-key operation services. In addition, the company processes and handles various materials comprising commodity resins, including high impact polystyrene, general purpose polystyrene, high and low density polyethylene, polypropylene, and SAN; engineered resins, such as nylon, ABS, poly carbonate, polyester, acetyl, PVC, kynar, ryton, and elastomers; and filled resins, including glass filled, carbon filled, talc filled, mineral filled, conductive resins, and blowing agents. Further, it provides secondary services, such as trimming, assembly, pad printing, hot stamping, special packaging, sonic welding and gluing, and mold maintenance services. Additionally, the company is involved in the designing of AutoCAD software. Phil-Good Products, Inc is based in Oklahoma City, Oklahoma.
Full PHGD Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.